1,082
Views
2
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

, , , , , , , & show all
Pages 891-896 | Received 04 Dec 2018, Accepted 14 Feb 2019, Published online: 25 Mar 2019
 

Disclosure statement

The authors are responsible for the content of the article. J.J.W.M. Janssen is an advisory board member for Abbvie, Incyte, Jazz Pharmaceuticals, and Pfizer, and has received research support funding from Novartis and Bristol Myers Squibb and speaker’s fees from Incyte and Pfizer. The other authors report no conflicts of interest.

Additional information

Funding

The data collection for this work was supported by an unrestricted grant by Novartis [CAMN107ENL04T].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.